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Abstract
Powering future generations of implanted medical devices will require cumbersome transcutaneous energy transfer or
harvesting energy from the human body. No functional solution that harvests power from the body is currently available,
despite attempts to use the Seebeck thermoelectric effect, vibrations or body movements. Glucose fuel cells appear more
promising, since they produce electrical energy from glucose and dioxygen, two substrates present in physiological fluids.
The most powerful ones, Glucose BioFuel Cells (GBFCs), are based on enzymes electrically wired by redox mediators.
However, GBFCs cannot be implanted in animals, mainly because the enzymes they rely on either require low pH or are
inhibited by chloride or urate anions, present in the Extra Cellular Fluid (ECF). Here we present the first functional
implantable GBFC, working in the retroperitoneal space of freely moving rats. The breakthrough relies on the design of a
new family of GBFCs, characterized by an innovative and simple mechanical confinement of various enzymes and redox
mediators: enzymes are no longer covalently bound to the surface of the electron collectors, which enables use of a wide
variety of enzymes and redox mediators, augments the quantity of active enzymes, and simplifies GBFC construction. Our
most efficient GBFC was based on composite graphite discs containing glucose oxidase and ubiquinone at the anode,
polyphenol oxidase (PPO) and quinone at the cathode. PPO reduces dioxygen into water, at pH 7 and in the presence of
chloride ions and urates at physiological concentrations. This GBFC, with electrodes of 0.133 mL, produced a peak specific
power of 24.4 mWm L
21, which is better than pacemakers’ requirements and paves the way for the development of a new
generation of implantable artificial organs, covering a wide range of medical applications.
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Introduction
Artificial implanted organs are an attractive solution to terminal
failures of organs such as pancreas, urinary sphincters, kidneys or
heart, but their development is thwarted by the problem of their
energy supply. Sealed batteries are adequate for pacemakers [1] that
consume about 10 mW, but not for more demanding applications, so
that cumbersome devices are still in use, and that innovative
implantable solutions are not even under research. An instance of a
cumbersome device is the manual Artificial Urinary Sphincter,
powered by the patient himself via a pump inserted in his scrotum,
which he has to press to enable micturition. This is the only solution
available today for the 10,000 new patients each year suffering from
incontinence after Radical Prostatectomy [2], while a Robotized
Artificial Urinary Sphincter would provide much more comfort and
ease of use, but would require about 200 mW in our estimations [3].
Though Wearable Artificial Kidneys begin to be developed [4],
research on Implanted Artificial Kidneys can hardly be envisaged
until a permanent source of power can provide the mean 20 mW
necessary for the osmotic work of kidneys in human beings. Of
course, energy can be provided by transcutaneous transfer, using
electro-magnetic coupling with an external source; but with the
exception of cochlear implants, where a simple and miniaturized
device can be used, transcutaneous energy transfer is very
constraining for the patient, who accepts this only in specific cases
such as artificial hearts [5], where immediate survival is at stake.
Physiological constraints limit to about 100 mW the expectation of
energy harvesting from Seebek thermoelectric effect, vibrations or
body movements [6].
Glucose fuel cells look very promising as a source of power for
implanted devices, because they could exploit glucose and dioxygen
from the ECF as a source of power. Pioneering work by Drake and
colleagues in the seventies raised hopes that abiotic catalysts could
oxidise glucose and reduce dioxygen sufficiently efficiently to enable
PLoS ONE | www.plosone.org 1 May 2010 | Volume 5 | Issue 5 | e10476powering of implanted medical devices [7]. This approach had been
abandoned until very recently [8], mainly because the power density
w a sn o ts u f f i c i e n t .G B F C se x p l o i te n z y m e sa sc a t a l y s t s ,w h i c ha r e
electrically wired by redox mediators [9–18]. Some GBFCs are at a
pre-industrial stage and feature a substantial power output, arising a
greatinterest asasourceof‘‘green power’’fornomadicdevices,while
others are based on microelectrodes, exhibiting excellent ratios of
power to electrode surface but low total power. Sony recently
produced an instance of the former, a GBFC of 80 mL generating
100 mW under 0.30 V when fed with a glucose solution of 400 mM
[19]. Unfortunately, glucose concentration in the Extra-Cellular
Fluid (ECF) is only 5 mM, and the concentration of molecular
oxygen, another important substrate of the GBFC, is markedly lower
in blood (45 mM) than in aqueous solutions under air (200 mM).
Heller and colleagues developed an instance of the latter: a micro
GBFC based on bilirubin oxidase. They obtained 4.4 mWa t3 7 uCi n
a physiological, glucose-enriched, buffer solution (pH 7.2, 0.14 M
NaCl, 20 mM phosphate, 30 mM glucose, 0.2 mM dioxygen) [20].
The most powerful GBFC was developed by Mano [21], who
increased the power density of Heller’s GBFC from 90 to
280 mWc m
22 at low glucose concentration by using Glucose
Oxidase (GOX) from Penicillium pinophilum, instead of the conven-
tional GOX from Aspergillus niger. However, all existing GBFC, pre-
industrial ones and microelectrode-based ones, use a biocathode
exclusively based on bilirubin oxidase or laccase enzymes for oxygen
reduction. The former requires low pH and is inhibited by chloride,
while the latter is inhibited by urate anions [22–24], thus preventing
their use in ECF (whose pH is about 7, and which contains chloride
Figure 1. Summary of the principle, preparation, implantation and operation of an implantable ‘‘Quinone-Ubiquinone Glucose
BioFuel Cell’’. (A) GBFC principle. The anode is constituted of a compacted graphite disc containing ubiquinone, glucose oxidase (GOX) and
catalase, while the cathode is composed of a compacted graphite disc containing quinhydrone and polyphenol oxidase (PPO). The cathode is
inserted in a dialysis bag (cut-off 100 g mol
21), in order to prevent quinhydrone diffusion. Both electrodes are packed in an external dialysis bag (cut-
off 6-8000 g mol
21) that lets glucose and dioxygen flow into the device. The current generated by the GBFC results from the oxidation of ubiquinol
combined with the reduction of quinone. Ubiquinol and quinone are enzymatically generated by GOX and PPO respectively. (B) GBFC preparation
and implantation. Each electrode measures 0.133 mL, so that the complete device can fit in the abdomen of the animal. The rat is anesthetized, a
median laparotomy is performed, and the GBFC is inserted into the retroperitoneal space in left lateral position. The catheters containing the copper
wires connected to the anode and cathode are subcutaneously tunnelled from the abdomen up to the back of the head of the animal, and
connected to the potentiostat. Finally, the muscular abdominal wall and the skin are separately sutured and the animal is allowed to recover from
anesthesia. (C) GBFC operation. 4 hours after implantation, cycles of discharge (at constant current of 10 mA) and of charge are recorded via a
potentiostat until sacrifice of the animal.
doi:10.1371/journal.pone.0010476.g001
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human body, a new concept of GBFC using enzymes compatible
with the characteristics of ECF has to be developed.
The ideal GBFC for operation in ECF should use enzymes and
redox mediators capable of working in ECF, and be robust and
easy to assemble into relatively big electrodes. We achieved this by
an original mechanical confinement of the enzymes and redox
mediators inside the electrodes. This enables use of several types of
enzymes and redox mediators, which allowed us to select those
that proved capable to work in the ECF and to produce a power
compatible with the requirements of a pacemaker and potentially
sufficient for powering a Robotized Artificial Urinary Sphincter.
Results
‘‘Mechanically Confined’’ implantable GBFCs working
with various enzymes and redox mediators
In contrast to current GBFCs, where enzymes and redox
mediators are covalently bound to the electrode, we mechanically
confined the contents of the electrodes, by use of dialysis
membranes and/or mechanical compression of graphite particles,
enzymes and redox mediators (Materials and Methods). This process,
summarized in Figure 1, required simple procedures involving
classical chemicals and materials, and allowed use of soluble
(quinone, hydroquinone) or poorly-soluble (ubiquinone, ubiquinol)
redox mediators, and of different enzymes (GOX at the anode,
PPO or urease at the cathode). One of these GBFCs used as fuel
not only glucose, but also urea.
In vitro demonstration of performance of our
‘‘Mechanically Confined’’ Quinone-Ubiquinone GBFC
with GOX and PPO
We experimented in vitro our Quinone-Ubiquinone GBFC, under
a concentration of glucose similar to that of ECF (5.5 10
23 mol L
21
glucose), and with a phosphate buffer of 2.5 10
22 mol L
21 yielding a
pH of 7.2 (thus simulating the pH of ECF, which is controlled by a
veryefficientbicarbonatebuffer),thetwoelectrodesbeingwrappedin
t h ee x p a n d e dP o l y T e t r a F l u r o r o E t h y l e n e( e x P T F E )m e m b r a n et h a t
was used later for in vivo experiments. The operational stability of this
GBFC was evaluated for a constant current of 10 mAi nt h e s e
conditions. The voltage and hence the cellpower decreased to ca. 9%
(0.15 mW) of the initial value over 1 hr, and then the GBFC
maintained a quasi-constant power (1.47 mW), delivering 10 mA
during 25 hrs. To demonstrate the stability of the GBFC, we
recorded its performances for 40 days (Fig. 2). Open circuit voltage
(OCV) was continuously monitored, while power-voltage profile and
discharge at constant current (5 mA) for 10 min were daily recorded.
The performances of the GBFC (power, open circuit voltage OCV
Figure 2. In vitro performances of a Quinone-Ubiquinone
GBFC. The GBFC is immersed in 50 mL HEPES buffer (2.5 10
22 mol L
21;
pH 7.2) containing 5.5 10
23 mol L
21 glucose and 0.15 mol L
21 NaCl.
(A) Power-voltage profile; i) first day, ii) second day, iii) sixth day, iv)
twenty fourth day, v) twenty ninth day vi) fortieth day. (B) Maximum
power (&) and OCV (+) as a function of time.
doi:10.1371/journal.pone.0010476.g002
Figure 3. Performance of a ‘‘Quinone-Ubiquinone GBFC’’ implanted in a male Wistar rat (514 g weight). (A) Power-voltage profile. A
peak power of 6.5 mW is observed at 0.13 V, yielding a maximum specific power of 24.4 mWm L
21. (B) Discharge curve. Discharge of the GBFC starts
4 hours after implantation. The chronopotentiometry was recorded for a constant current (10 mA). A stable production of more than 2 mWi s
observed for several hours.
doi:10.1371/journal.pone.0010476.g003
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average maximum power from 30 to 40 days was about 1.65 mW
(standard deviation 0.13 mW), reflecting an excellent operational
stability. The performance of the GBFC was not diminished over
time, since the OCV reached 250 mV during the last two weeks,
discharge curves keeping the same shape.
In vivo demonstration of performance of our
Quinone-Ubiquinone GBFC
Having shown in vitro power generation by our Quinone-
Ubiquinone GBFC, we next ascertained whether it was able to
work when implanted in an animal. A male Wistar rat (514 g
weight) was anesthetized and this GFBC was surgically inserted
into its retroperitoneal space, enabling glucose and O2 from the
E C Ft of l o wi n t ot h eG B F C .A f t e rt h er a th a dr e c o v e r e df r o m
anesthesia and was allowed unrestricted movement, cell
performance was evaluated (Fig. 3). The OCV of the GBFC
was 0.275 V while the maximum power was 6.5 mW( a t0 . 1 3V ) ,
yielding a maximum specific power of 24.4 mWm L
21.T h e
voltage decreased from 0.27 to 0.22 V during the first 80 min
and was then quasi-stable, with a slow decrease of 9 mV h
21.
These experiments confirmed the capacity of a GBFC to work
in ECF and to produce 2 mW( 7 . 5 2 mWm L
21)f o rs e v e r a l
hours.
Demonstration of performance over an extended period
of time
In order to power implanted organs, a GBFC must prove over an
extended period of time that it can remain functional, and that it can
extract sufficient glucose and O2 f r o mt h eE C F .W ec a r r i e do u t
stability experiments consisting in daily recording the power-voltage
profile (during discharges at 5 mA for 10 min) for an implanted
GBFC. As previously observed, after an initial increase, the
performances (power 1.8 mWa n dO C V2 0 0m V )f o ras m a l l e rr a t
(444 g weight) remained stable (standard deviation 0.17 mW) until
sacrificeofthe animalafter11days.Regardinglong termglucoseand
O2 e x t r a c t i o nf r o mt h eE C F ,w ei m p l a n t e di nt h er e t r o p e r i t o n e a l
space of a rat a dialysis tubing of 4 mL wrapped in an exPTFE
coating, containing GOX and catalase, and monitored during 3
months the production of gluconate in the daily urines of the animal
(Materials and Methods S1). At sacrifice, no sign of inflammatory
reaction against the implant was observed, while a neo-vascular
network had developed around the implant (Fig. 4). A mean daily
production of 555 mmoles day
21 of gluconate was measured.
In vitro and in vivo demonstration of performance of
‘‘Mechanically Confined’’ Quinhydrone pH-based Glucose
and Urea BioFuel Cell working with GOX and urease
In order to demonstrate that the concept of ‘‘mechanical
confinement’’ allows use of several types of enzymes and redox
mediators, we developed and tested another instance of a
‘‘Mechanically Confined’’ GBFC, based on the dependence on
pH of the potential of quinhydrone, an equimolar mixture of
quinone (Q) and hydroquinone (QH2). The principle of this
BioFuel Cell, which uses as fuel both glucose and urea and is
detailed in Materials and Methods, is summarized in Figure 5. An in
vitro demonstrator showed that this principle led to a DpH of 4.8
generating under 10 mA a potential difference of 265 mV,
corresponding to a maximum power of 2.65 mW. Power of
3 nW was obtained during 45 min after implantation in the
retroperitoneal space of a rat (Fig. 5), illustrating the viability of
this concept in vivo.
Discussion
These experiments are the first ones reporting successful
operation of a GBFC inside an animal. This was made possible
by an innovative reduction of O2 into water by PPO, an enzyme
capable to work efficiently in the specific conditions of the Extra-
Cellular Fluid, which is not the case of enzymes such as laccase or
bilirubin oxidase, classically used in GBFCs. Use of this enzyme
was facilitated by the application of a very simple process of
construction of the electrodes, based on mechanical confinement
of redox mediators and of enzymes, which provides a cheap and
simple alternative to the classical electric wiring obtained by
covalent binding of these elements on an electron collector. This
process allows use of virtually any type of enzymes and redox
mediators that would be capable to work in the ECF. We proved
that pH-based BioFuel Cells exploiting as fuel not only glucose,
but also urea, could work. Though the enzymes we used for this
pH-based BioFuel Cell work in ECF conditions, the potential of
this specific approach seems today limited to in vitro applications,
until a solution is found to isolate the GBFC from the bicarbonate
buffer of the ECF. Indeed, the difference of power between in vitro
and in vivo experiments suggests that this very efficient buffer
(about 25 mM) prevents in vivo application of this specific
approach.
We obtained a stable in vivo production of 2 mW in a device of
some mL whose electrodes are 0.133 mL. This power may look
limited, when compared to the 4.4 mW obtained by Heller and
colleagues [20]. However, the major difference lies in the fact that
our performances were recorded with a device implanted inside
the ECF of a rat, while the results reported by Heller and
colleagues were obtained in vitro. Besides, in the latter experiment,
the solution was enriched in glucose (30 mM glucose) and under
air (so that the concentration of dioxygen was 200 mM), which are
significantly different conditions with respect to those of ECF
(where glucose is below the 5 mM of blood glucose level and
dioxygen below the 45 mM of venous level).
An important issue will be to demonstrate that our GBFC can
work during months or years when implanted in animals. We
Figure 4. Implants containing both Glucose Oxidase and
catalase, before and after implantation in a rat. Implants
containing both GOX and catalase, immobilized on barium alginate
beads, in dialysis tubing wrapped in an exPTFE coating. (A) Before
implantation. (B) After 3 months of implantation. A neo-vascular
network can be seen, no sign of inflammation is present, proving the
good tolerance of the rat for the implant.
doi:10.1371/journal.pone.0010476.g004
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operational during 3 months, and kept capable to produce about
100 times more gluconate than what our GBFC did to produce
2 mW. Indeed, according to Faraday’s law, since in our GBFC
each mole of glucose provides two moles of electrons, our GBFC
consumes each day 4.5 mmoles of glucose, in order to produce
2 mW under 200 mV. This figure should be compared to the daily
consumption of 555 mmoles of glucose reported in section 2.4 with
a 4 mL device containing GOX. This experiment tends to prove
that extraction of glucose from ECF will not be the limiting factor
to improve the performance of our GBFC. The fact that GOX
remained operational during 3 months is very encouraging, and is
corroborated by experiments reported by Minteer [25], who
proved that implanted enzymes could be kept fully operational
during more than one year, in conditions similar to the ones
requested by our GBFC concept.
With its present design, our GBFC is capable to produce a peak
power of 24.4 mWm L
21, and a stable power of more than
7.52 mWm L
21. This is already significant with respect to the
requirements of medical devices (typically 10 mW for a pacemaker
[1]). Though sealed batteries are perfectly adequate for pacemak-
ers (they have to be surgically replaced after 5 to 8 years, which is
quite acceptable), their use in applications requesting 200 mWo r
more would require significant increase in the performance they
reach today in clinical practice (since they would have to be
replaced about twice a year). It should be noted that early
pacemakers had volumes up to 90 mL
1, which shows that
implanted devices of such a big volume can be accepted, provided
that there is a significant medical added-value. With our present
level of stable performance, we could expect to generate in an
animal such as a pig about 1 mW with a battery of about 133 mL.
We are beginning to explore the possibility to use this approach to
power a Robotized Artificial Urinary Sphincter, which requires in
our estimations about 200 mW [3], corresponding to a GBFC
similar to the ones we tested, but of about 26 mL. This is about the
size of the balloon that is implanted today in the abdomen of
patients to whom manually-controlled Artificial Urinary Sphinc-
ters are proposed [2]. We also expect significant improvement
from the use of other enzymes and redox mediators. Indeed, the
concept of mechanical confinement enables straightforward
Figure 5. Implantable ‘‘Quinhydrone pH-based Glucose and Urea BioFuel Cell’’ with mechanically confined electrodes. (A) Schematic
representation. In each electrode, the redox species, quinone (Q) and hydroquinone (QH2) are confined close to a carbon felt by a first dialysis bag (nominal
cut-off of 100 g mol
21). This bag separates the redox species from the enzymes contained in a second dialysis bag with a nominal cut-off of 6–
8000 g mol
21. This second dialysis bag contains GOX and catalase for the anode, and urease for the cathode. The two electrodes are packed together in a
DacronH sleeve.(B)Electro-chemicalreactions at theelectrodes.ActionoftheGOXat thecathodelocally decreasesthe pH,whileactionoftheureaseat the
anode locally increases pH. Nernst law governs the difference of potential between anode and cathode (subscripts a is used in this equation to identify pH
andconcentrationsofspeciesattheanode,subscriptcdenotingthecathode).Atthecathode,quinone(Q)isreducedintohydroquinone(QH2), while at the
anode hydroquinone (QH2)isoxidisedintoquinone(Q).(C)Dischargecurveunder100 nA.Thiscurvewasrecordedafterimplantationintheretroperitoneal
space of a rat, for a constant current of 100 nA. It corresponds to a mean power of 3 nW during 45 minutes.
doi:10.1371/journal.pone.0010476.g005
A GBFC Implanted in Rats
PLoS ONE | www.plosone.org 5 May 2010 | Volume 5 | Issue 5 | e10476integration of any such enzyme or redox mediator, so that it is not
unrealistic to get with GBFCs exploiting the concepts we described
to produce tens of mW or more, thus opening possibilities for
research on new generations of implanted medical devices.
Materials and Methods
Ethics Statements
The care of the rats was approved by the European
Communities Council Directive Animal Care and Use Committee
and performed in accordance to their guiding principles
(European Communities Council Directive L358-86/609/EEC).
All protocols involving living animals were performed under
license from the French Ministry of Agriculture (License number
38018).
‘‘Mechanically Confined’’ Quinone-Ubiquinone GBFC
with GOX and PPO
Mechanical compression of graphite particles, enzymes and
redox mediators provided mechanically stable composite discs of
0.133 mL, and allowed the coimmobilisation of poorly soluble
redox mediators such as coenzyme Q10 or ubiquinone, and hence
a non-covalent electric wiring (Materials and Methods S1). A
platinum wire fixed on one side of the disc by a conductive
adhesive connected each composite graphite disc. A schematic
representation of our process is outlined in Figure 1. The anode
contained a mixture of graphite, ubiquinone, glucose oxidase
(GOX) and catalase. The cathode contained quinhydrone,
combined with polyphenol oxidase (PPO) and graphite, and was
inserted in a cellulose acetate dialysis bag with a nominal cut-off of
100 g mol
21 to prevent diffusion of quinhydrone. The two
electrode discs were placed face to face, with the platinum wire
outside, and then inserted in an external dialysis bag with a
nominal cut-off of 6-8000 g mol
21. Each isolated platinum wire
was inserted in a catheter onto which the external dialysis bag was
sealed. The external dialysis bag prevented any diffusion of
enzymes. Glucose and O2 from the outside flowed into the device
across the external dialysis bag. In presence of glucose, GOX
generated ubiquinol from ubiquinone while catalase eliminated
H2O2 produced by the side reaction of dioxygen with GOX. In
the presence of dioxygen, PPO catalysed the oxidation of phenols
and di-phenols into quinoid products, dioxygen being reduced into
water. Thus, at the cathode PPO regenerated the quinone form
reduced previously into hydroquinone by the battery reaction. In
contrast to laccase and bilirubin oxidase, PPO could efficiently
operate at pH 7 and was not inhibited by products present in
physiological fluids. The circuit was then closed with a potentiostat
enabling automatic external resistance adaptation in order to keep
a constant current in the circuit.
‘‘Mechanically Confined’’ Quinhydrone pH-based Glucose
and Urea BioFuel Cell working with GOX and urease
Each electrode comprised a carbon felt inserted in a first dialysis
bag with a nominal cut-off of 100 g mol
21, initially containing
quinhydrone (Materials and Methods S1). Each bag was then inserted
in a second dialysis bag with a nominal cut-off of 6–8000 g mol
21,
containing GOX and catalase for the anode, and urease for the
cathode. The two electrodes were packed together in an exPTFE
membrane. In the presence of O2, GOX and catalase catalyze the
production of gluconate and protons at the cathode, while urease
activity on urea creates hydroxyl ions at the anode. According to
the Nernst equation, the gradient of pH between the two
electrodes, which contain the same couple of pH-sensitive redox
mediators, modifies the electrical potential of each electrode and
generates electron exchanges.
Materials and Methods S1
Detailed presentations of the following materials and methods
are described in the separate ‘‘Materials and Methods S1’’ file.
Supporting Information
Materials and Methods S1 Supplementary Materials and
Methods for A Glucose BioFuel Cell Implanted in Rats.
Found at: doi:10.1371/journal.pone.0010476.s001 (0.07 MB
DOC)
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